Cinnarizine: A Contemporary Review
- 209 Downloads
Cinnarizine, is approved for nausea, vomiting, motion sickness, inner ear disorders and is considered as first-line pharmacotherapy for management of vertigo. It acts by anti-vasoconstrictor activity, reducing blood viscosity and reducing nystagmus in labyrinth. Lack of adequate literature on clinical evidence of cinnarizine and its combination (dimenhydrinate) in vertigo management prompted this review. A specific MEDLINE literature search strategy was designed combining Medical Subject Headings, free-text keywords (like cinnarizine and vertigo) using Boolean operators (1970–2016) for clinical studies, clinical reviews and meta-analyses of cinnarizine. Analyses of studies validated cinnarizine’s efficacy in peripheral and central vertigo versus placebo or other therapies, and was well-tolerated by the patients recruited across different studies. Cinnarizine and/ or its combinations are favorable in management of vestibular disorders wherein cinnarizine acts predominantly peripherally on labyrinth and dimenhydrinate acts centrally on vestibular nuclei and associated centers in brainstem. Combination therapy of cinnarizine and/ or its combinations demonstrated a better safety profile than either of the mono-components, offering a viable therapeutic option in vertigo management.
KeywordsCinnarizine Vertigo Dimenhydrinate Drug combinations
Dr. Sonia Philipose (SIRO Clinpharm Pvt. Ltd.) provided editorial support for this manuscript. This work was supported by funding from Janssen India.
Compliance with Ethical Standards
Conflict of interest
Dr. Ravi Santani and Dr. Prashant Narang are employees and/or shareholders of Janssen, India. All authors contributed to the data interpretation and development of the review. All authors met ICMJE criteria and all those who fulfilled those criteria are listed as authors. All authors had access to the study data, provided direction and comments on the manuscript, made the final decision about where to publish these data and approved submission to the journal.
- 3.National formulary of India, fourth edition, 2011. http://www.cdsco.nic.in/writereaddata/NFI_2011%20(1).pdf. Accessed 17 Oct 2016
- 4.Drugs Controller General of India. List of approved drug from 01.01.2010 to 31.12.2010. http://www.cdsco.nic.in/writereaddata/list-of-approved-drug-from-01-01-2010-TO-31-12-2010.pdf. Accessed 17 Oct 2016
- 5.Oosterveld WJ (1999) Cinnarizine in the vertiginous syndrome. In: Towse G (ed) cinnarizine and the vertiginous syndrome. International Congress and Symposium Series No. 33. Royal Society of Medicine and Academic Press Inc, London, pp 29–37Google Scholar
- 17.Godfraind T, Towse G, Van Nueten J (1982) Cinnarizine: a selective calcium entry blocker. Drugs Today 18:27–42Google Scholar
- 21.Stugeron® (cinnarizine). http://www.janssen.com/southafrica/sites/www_janssen_com_southafrica/files/product/pdf/stugeron_pi_mar_2013_eng_port_0.pdf. Accessed 24 Sept 2016
- 23.Hahn A, Novotný M, Shotekov PM, Cirek Z, Bognar-Steinberg I, Baumann W (2011) Comparison of cinnarizine/dimenhydrinate fixed combination with the respective monotherapies for vertigo of various origins: a randomized, double-blind, active-controlled, multicentre study. Clin Drug Investig 31:371–383PubMedCrossRefGoogle Scholar
- 25.STUGERON. www.meppo.com/pdf/drugs/2444-stugeron-1329753152.pdf. Accessed 24 Sept 2016
- 31.Scholtz A-W, Steindl R, Burchardi N, Bognar-Steinberg I, Baumann W (2012) Comparison of the therapeutic efficacy of a fixed low-dose combination of cinnarizine and dimenhydrinate with betahistine in vestibular neuritis: a randomized, double-blind, non-inferiority study. Clin Drug Investig 32:387–399PubMedCrossRefPubMedCentralGoogle Scholar
- 32.Trkanjec Z, Aleksić-Shibabi A, Demarin V (2007) Pharmacotherapy of vertigo. Rad za Medicinske Znanosti 69–76Google Scholar
- 33.Whaetley D (1973) Reports from the general practitioner research group; anthistamines and phenothiazine compared in vertigo. Practitioner 211:224–227Google Scholar
- 39.Amery WK, Oosterveld WJ (1975) An evaluation of cinnarizine in aged patients with vertiginous complaints-a multicentre trial. Acta Ther 1:39–43Google Scholar
- 40.Udvarhelyi A (1978) Comparative study of the effect of devincan and stugeron in patients suffering from cerebrovascular diseases treated at medical departments. Ther Hung (English edition) 26:29–32Google Scholar
- 42.Cirek Z, Schwarz M, Baumann W, Novotny M (2005) Efficacy and tolerability of a fixed combination of cinnarizine and dimenhydrinate versus betahistine in the treatment of otogenic vertigo: a double-blind, randomised clinical study. Clin Drug Investig 25:377–389PubMedCrossRefPubMedCentralGoogle Scholar
- 44.Martines F, Agrifoglio M, Bentivegna D, Mucia M, Salvago P, Sireci F et al (2012) Treatment of tinnitus and dizziness associated vertebrobasilar insufficiency with a fixed combination of cinnarizine and dimenhydrinate. Acta Med Mediterr 28:291–296Google Scholar
- 45.Pytel J, Nagy G, Tóth A, Spellenberg S, Schwarz M, Répassy G (2007) Efficacy and tolerability of a fixed low-dose combination of cinnarizine and dimenhydrinate in the treatment of vertigo: a 4-week, randomized, double-blind, active-and placebo-controlled, parallel-group, outpatient study. Clin Ther 29:84–98PubMedCrossRefGoogle Scholar